Human Growth Hormones Market to Expand at 9.46% CAGR Between 2022 and 2030

Market Research Future (MRFR) has published a cooked research report on the “Global Growth Hormone Market” that contains information from 2022 to 2030. The Global Growth Hormone Market is estimated to register a CAGR of 9.46% during the forecast period of 2022 to 2030.

Market Highlights

The Global growth hormone market is accounted to register a CAGR of 9.46% during the forecast period and is estimated to reach USD 9.46 Billion by 2030.

The "Global Growth Hormone Market" refers to the worldwide market for growth hormone (GH) products. Growth hormone is a peptide hormone that plays a vital role in stimulating growth, cell reproduction, and regeneration in humans and animals.

The market for growth hormone products is typically driven by factors such as increasing cases of growth-related disorders, advancements in biotechnology and genetic engineering, rising healthcare expenditure, and the growing awareness of growth hormone therapies.

Key Market Players:

MRFR recognizes the following companies as the key players in the Global Growth Hormone Market— Novo Nordisk A/S, Pfizer Inc., Ascendis Pharma A/S, EMD Serono, Ferring B.V., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd, Sandoz International GmbH, AnkeBio Co. Ltd, Ipsen Pharma, and Genentech.

Segment Analysis

The Global Growth Hormone Market has been segmented based on brand, application and sales channel.

On the basis of brand, the market is segmented into norditropin, genotropin, humatrope and others. This is owing to the growing occurrences of growth hormone deficiency diseases, and technological advances, such as recombinant DNA technology, which is anticipated to fuel the growth of the segment.

Based on application, the market has been segmented into Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Idiopathic Growth Hormone Deficiency and Small for Gestational Age. Growth hormone deficiency segment is due to the growing prevalence of GHD, increasing penetration of drugs by prominent market players, and increasing awareness about the disease.

Based on sales channel, the market has been segmented into hospital pharmacies, retail pharmacies, online pharmacy and specialty pharmacy. Online pharmacy is projected to be the fastest-growing segment. Moreover, hospital pharmacies are preferred the synthetic or recombinant variants of growth hormone and the ease of availability.

Explore In-depth Details: Human Growth Hormone Market Research Report

Regional Analysis

The Global Growth Hormone Market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Growth Hormone Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Growth Hormone Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Global Growth Hormone Market comprises of Middle East, Africa, and Latin America.

North America is one of the major markets for growth hormone products. Due to factors such as advanced healthcare infrastructure, high healthcare expenditure, and a relatively large number of patients with growth hormone deficiencies.

Europe is another significant market for growth hormone products. The demand in Europe is driven by increasing awareness of growth hormone therapies, a rise in the prevalence of growth-related disorders, and favorable reimbursement policies.

The Asia-Pacific region is witnessing rapid growth in the demand for growth hormone products. Factors such as a large population base, rising healthcare expenditure, and improving access to medical treatments contribute to the expanding market in this region.

Furthermore, the rest of the world's Global Growth Hormone Market is divided into the Middle East, Africa, and Latin America. Latin America also plays a role in the global growth hormone market. The increasing prevalence of growth-related disorders and improving healthcare infrastructure contribute to the market's growth in this region.

Key Findings of the Study

• North America is one of the major markets for growth hormone products. Due to factors such as advanced healthcare infrastructure, high healthcare expenditure, and a relatively large number of patients with growth hormone deficiencies.


• Based on application, the market has been segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency holding the largest market in 2022.


• Novo Nordisk A/S, Pfizer Inc., Ascendis Pharma A/S, EMD Serono, Ferring B.V., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd, Sandoz International GmbH, AnkeBio Co. Ltd, Ipsen Pharma and Genentech.